This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
UBS Remains a Buy on Wuxi Biologics (Cayman) (WXIBF)
In a report released on May 26, from UBS maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$49.30. The company’s shares closed last Tuesday at HK$34.38.
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wuxi Biologics (Cayman) with a HK$45.29 average price target, a 31.74% upside from current levels. In a report released on May 14, Morgan Stanley also maintained a Buy rating on the stock with a HK$50.00 price target.
The company has a one-year high of HK$44.00 and a one-year low of HK$23.10. Currently, Wuxi Biologics (Cayman) has an average volume of 28.71M.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
